• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Top 5 Heart Failure Apps for Primary Care Providers & Patients

News
Slideshow

From a mobile fluid tracker to an app with a 3-D beating heart, these are the top 5 heart failure apps that every primary care physician and patient should know about. 

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose

Sydney Jennings
April 25th 2025
Article

Your daily dose of the clinical news you may have missed.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Sydney Jennings
April 11th 2025
Article

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo / image credit ©Tefi/stock.adobe.com

Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo

Grace Halsey
April 1st 2025
Article

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology

Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

Grace Halsey
March 31st 2025
Article

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

© 2025 MJH Life Sciences

All rights reserved.